Literature DB >> 3488071

The treatment of hairy-cell leukaemia with 2'-deoxycoformycin.

J B Johnston, R I Glazer, L Pugh, L G Israels.   

Abstract

Eight patients with hairy-cell leukaemia (HCL) complicated by pancytopenia were treated with low dose regimens of the adenosine deaminase (ADA) inhibitor 2'-deoxycoformycin (DCF). All patients had significant haematological and clinical improvement. One patient who had been splenectomized and five patients with mild to moderate splenomegaly achieved normal blood counts within 2 months, which have been maintained for up to 18 months. Complete remissions occurred in two patients and four patients had 50-95% marrow clearance of hairy cells. The initial DCF treatments produced a 1-3 g/dl fall in the haemoglobin levels and one patient had a temporary reduction in granulocyte and platelet counts. Five patients had nausea/vomiting, and/or lethargy following DCF, but there was no correlation between the plasma levels of deoxyadenosine and adenosine and the incidence or severity of these side effects. An increased incidence of infection and drug hypersensitivity may reflect the effects of DCF on the immune system. Low dose DCF is a highly effective agent in HCL.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3488071     DOI: 10.1111/j.1365-2141.1986.tb07530.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  12 in total

Review 1.  Hairy cell leukemia: present and future directions.

Authors:  Robert J Kreitman
Journal:  Leuk Lymphoma       Date:  2019-05-09

Review 2.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 3.  Hairy cell leukemia: clinical features and therapeutic advances.

Authors:  B C Lembersky; H M Golomb
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  Hypersensitivity reactions to deoxycoformycin.

Authors:  P J O'Dwyer; S A King; E Eisenhauer; J L Grem; D F Hoth
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Factors influencing the inhibition of repair of irradiation-induced DNA damage by 2'-deoxycoformycin and deoxyadenosine.

Authors:  A Begleiter; L Verburg; L G Israels; J B Johnston
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 6.  The optimal management of hairy cell leukaemia.

Authors:  R Gollard; T C Lee; L D Piro; A Saven
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 7.  Pentostatin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in lymphoproliferative disorders.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 8.  Update on hairy cell leukemia.

Authors:  Robert J Kreitman; Evgeny Arons
Journal:  Clin Adv Hematol Oncol       Date:  2018-03

9.  Deoxycoformycin in the treatment of mature B-cell malignancies.

Authors:  C Dearden; D Catovsky
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

Review 10.  Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.

Authors:  Sheena N Ramasamy; Cameron S Korb-Wells; Diluk R W Kannangara; Myles W H Smith; Nan Wang; Darren M Roberts; Garry G Graham; Kenneth M Williams; Richard O Day
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.